20 to 50     : Dose as in normal renal function
10 to 20     : Dose as in normal renal function
<10           : Dose as in normal renal function
DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES
CAPD                :Unknown dialysability. Dose as in normal renal function
HD                     :Unknown dialysability. Dose as in normal renal function
HDF/high flux   :Likely to be dialysed. Dose as in normal renal function
CAV/VVHD      :Unknown dialysability. Dose as in normal renal function
IMPORTANT DRUG INTERACTIONS
Potentially hazardous interactions with other drugs
Analgesics: avoid concomitant use with dextromethorphan; avoid concomitant use with pethidine (risk of serious adverse reactions) – allow at least 14 days before starting pethidine
Antidepressants: avoid concomitant use with other MAOIs (can lead to hypertensive crisis) – allow at least 14 days before starting a MAOI; avoid concomitant use with fluoxetine and fluvoxamine; allow 5 weeks between stopping fluoxetine and starting rasagiline; allow 14 days between stopping rasagiline and starting fluoxetine or fluvoxamine; increased CNS toxicity with SSRIs and tricyclics
Sympathomimetics: concomitant use is not recommended
ADMINISTRATION
Reconstition
–
Route
Oral
Rate of Administration
–
Comments
–
OTHER INFORMATION
Rasagiline is an irreversible selective inhibitor of monoamine oxidase type B.